Matsumoto K, Kanmatsuse K
Department of Medical Technology, College of Medical Sciences, Saitama Prefectural University, Koshigaya, Japan.
Clin Nephrol. 2001 Apr;55(4):269-74.
Vascular endothelial growth factor (VEGF) is a selective endothelial mitogen and vascular permeability factor (VPF), that is mainly produced by activated monocytes/macrophages and T cells. To our knowledge, very little is known about the involvement of VEGF in minimal-change nephrotic syndrome (MCNS). The aim here was to define further the involvement of VEGF in MCNS.
Urine samples were obtained from 20 MCNS patients. The disease controls included 20 patients with IgA nephropathy (IgAN). The samples were assayed for VEGF protein by a sandwich enzyme-linked immunosorbent assay (ELISA).
Compared with normal controls, markedly increased urinary levels of VEGF were detected in both MCNS and IgAN patients with the nephrotic syndrome (NS). The urinary VEGF (uVEGF) levels correlated with the degree ofproteinuria in MCNS and IgAN patients. Moreover, when individual MCNS patients were followed through their clinical illness, uVEGF levels were increased during the active phase and decreased as the patients went into remission. Our main concern is to distinguish between two possibilities: Increases in uVEGF excretion might indeed relate to specific glomerular pathology and thus have a pathophysiological role. Alternatively, uVEGF may be derived from the circulation and as such may be nothing more than an assay for proteinuria. In fact, given the strict correlation between uVEGF excretion and the amount of proteinuria, the second possibility appears quite conceivable.
Therefore, this may be a coincidental finding which has no bearing on the pathophysiology of MCNS.
血管内皮生长因子(VEGF)是一种选择性内皮细胞促分裂原和血管通透性因子(VPF),主要由活化的单核细胞/巨噬细胞和T细胞产生。据我们所知,关于VEGF在微小病变肾病(MCNS)中的作用了解甚少。本研究的目的是进一步明确VEGF在MCNS中的作用。
收集20例MCNS患者的尿液样本。疾病对照组包括20例IgA肾病(IgAN)患者。采用夹心酶联免疫吸附测定(ELISA)法检测样本中的VEGF蛋白。
与正常对照组相比,MCNS和IgAN肾病综合征(NS)患者的尿VEGF水平均显著升高。MCNS和IgAN患者的尿VEGF(uVEGF)水平与蛋白尿程度相关。此外,对个别MCNS患者进行临床随访时发现,uVEGF水平在疾病活动期升高,病情缓解时下降。我们主要关注两种可能性:uVEGF排泄增加可能确实与特定的肾小球病理改变有关,因此具有病理生理作用。或者,uVEGF可能来源于循环系统,因此可能仅仅是蛋白尿的一种检测指标。事实上,鉴于uVEGF排泄与蛋白尿程度之间的严格相关性,第二种可能性似乎相当合理。
因此,这可能是一个偶然发现,与MCNS的病理生理学无关。